Trial Profile
A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Fosdevirine (Primary) ; Darunavir; Etravirine; Raltegravir; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SONNET
- Sponsors ViiV Healthcare
- 31 Jul 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 24 Oct 2013 Results reporting the incidence of new-onset seizures which subsequently led to trial discontinuation published in Antiviral Therapy.
- 02 Nov 2010 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov.